

Liver (Including Intrahepatic Bile Ducts)

**Protocol applies to hepatocellular carcinoma
and cholangiocarcinoma.**

*Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Hepatectomy, Partial or Complete**

Authors

John R. Craig, MD

Co-Director of Laboratories, St. Jude Medical Center, Fullerton, California

Alberto M. Marchevsky, MD

Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California

For the Members of the Cancer Committee, College of American Pathologists

Previous contributors: Stephen G. Ruby, MD; Gregorio Chejfec, MD;
John A. Payne, MD; Jerome B. Taxy, MD; Kay Washington, MD; Christopher Willett, MD;
James Williams, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

LIVER: Resection

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type**

- Right lobectomy
 Extended right lobectomy
 Medial segmentectomy
 Left lateral segmentectomy
 Total left lobectomy
 Explanted liver
 Other (specify): _____
 Not specified

Focality

- Solitary (specify location): _____
 Multiple (specify location): _____

Tumor Size

- Greatest dimension: ____ cm
 *Additional dimensions: ____ x ____ cm
 Cannot be determined (see Comment)

MICROSCOPIC**Histologic Type**

- Hepatocellular carcinoma
 Fibrolamellar hepatocellular carcinoma variant (specify): _____
 Combined hepatocellular and cholangiocarcinoma
 Cholangiocarcinoma, intrahepatic
 Bile duct cystadenocarcinoma
 Undifferentiated carcinoma
 Other (specify): _____
 Carcinoma, type cannot be determined

4

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Histologic Grade

- Not applicable
 GX: Cannot be assessed
 GI: Well differentiated
 GII: Moderately differentiated
 GIII: Poorly differentiated
 GIV: Undifferentiated/anaplastic
 Other (specify): _____

Pathologic Staging (pTNM)Primary Tumor (pT)

- pTX: Cannot be assessed
 pT0: No evidence of primary tumor
 pT1: Solitary tumor with no vascular invasion
 pT2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm
 pT3: Multiple tumors more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
 pT4: Tumor(s) with direct invasion of adjacent organs other than the gallbladder or perforation of visceral peritoneum

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
 pN0: No regional lymph node metastasis
 pN1: Regional lymph node metastasis
 Specify: Number examined: ____
 Number involved: ____

Distant Metastasis (pM)

- pMX: Cannot be assessed
 pM1: Distant metastasis
 *Specify site(s), if known: _____

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Margins (check all that apply)Parenchymal Margin

- Cannot be assessed
 Uninvolved by invasive carcinoma
 Distance of invasive carcinoma from closest margin: ___ mm
 Specify margin: _____
 Involved by invasive carcinoma

Bile Duct Margin (Cholangiocarcinoma Only)

- Cannot be assessed
 Uninvolved by invasive carcinoma
 * Carcinoma in situ absent
 * Carcinoma in situ present
 Involved by invasive carcinoma

Other Margin

- Specify margin: _____
 Cannot be assessed
 Uninvolved by invasive carcinoma
 Involved by invasive carcinoma

***Venous (Large Vessel) Invasion (V)**

- * Absent
 * Present
 * Indeterminate

***Additional Pathologic Findings (check all that apply)**

- * None identified
 * Hepatocellular dysplasia
 * Ductal dysplasia
 * Cirrhosis/fibrosis
 * Iron overload
 * Hepatitis (specify type): _____
 * Other (specify): _____

***Comment(s)**

6 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.